Evidence map›Paper›PMID 26025441›Full record

ArticleJournal of experimental & clinical cancer research : CR2015

Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies.

Giovanni Cigliana, Eleonora Torti, Francesca Gulli, Elena De Santis, Maria Teresa Dell'Abate, Luigi Colacicco, Francesco Pisani, Laura Conti, Umberto Basile

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Giovanni CiglianaDepartment of Prevention and Diagnostic Oncology, Laboratory of Clinical Pathology -National Cancer Institute "Regina Elena", Rome, Italy. cigliana@ifo.it.
Eleonora TortiDepartment of Laboratory Medicine, School of Medicine, Catholic University of the Sacred Heart, Largo A. Gemelli 8, Rome, ZIP CODE: 00168, Italy. etorti@gmail.com.
Francesca GulliSchool of Medicine - Institute of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy. fragulli@tiscali.it.
Elena De SantisDepartment of Laboratory Medicine, School of Medicine, Catholic University of the Sacred Heart, Largo A. Gemelli 8, Rome, ZIP CODE: 00168, Italy. elena.desantis83@gmail.com.
Maria Teresa Dell'AbateDepartment of Laboratory Medicine, School of Medicine, Catholic University of the Sacred Heart, Largo A. Gemelli 8, Rome, ZIP CODE: 00168, Italy. dellabatemariateresa@gmail.com.
Luigi ColaciccoDepartment of Laboratory Medicine, School of Medicine, Catholic University of the Sacred Heart, Largo A. Gemelli 8, Rome, ZIP CODE: 00168, Italy. ginocolacicco@gmail.com.
Francesco PisaniHematology and Transplantation, Italian National Cancer Institute "Regina Elena", Rome, Italy. pisani@ifo.it.
Laura ContiDepartment of Prevention and Diagnostic Oncology, Laboratory of Clinical Pathology -National Cancer Institute "Regina Elena", Rome, Italy. laura.conti@ifo.it.
Umberto BasileDepartment of Laboratory Medicine, School of Medicine, Catholic University of the Sacred Heart, Largo A. Gemelli 8, Rome, ZIP CODE: 00168, Italy. umberto.basile@rm.unicatt.it.
Università Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMonoclonal gammopathies encompass a wide range of diseases characterized by the monoclonal expansion of a B-cell clone. Despite emerging therapeutic strategies, chances of survival of patients who are affected are still scarce, which implies that new tools are necessary not only for the diagnosis but also for the follow-up of patients affected by such diseases. In this context, the use of free light chains (FLCs) has been incorporated into many guidelines. Likewise, tumor microenvironment is consistently gaining importance as role player in tumor pathogenesis. Specifically, Syndecan-1 (CD138), a heparan-sulfate proteoglycan is attracting interests as it is highly expressed and shed by myeloma plasma-cells. The aim of our study was to analyze CD138 levels in the serum of patients affected by multiple myeloma or light chain only disease, and to compare the values obtained with free light chain (FLC) kappa, lambda and FLC ratio in both groups of patients.

methods84 patients affected by Multiple Myeloma and Light Chain Myeloma were recruited for this study. Serum CD138 was assessed by ELISA (Diaclone Research, France) and FLC values were quantified by nephelometry (Freelite TM Human Kappa and Lambda Free Kits, The Binding Site, UK). Data was analyzed by GraphPad Prism software and Statgraph.

resultsWe observed higher CD138 mean values in myeloma patients compared to the light chain only myeloma group. A positive linear regression of CD138 and FLC was observed in the light chain only cohort as opposed to myeloma patients which show an inverse trend.

conclusionsThe study highlighted an existing relationship between FLCs and CD138 and wishes to seek also a correlation in order to rapidly and efficiently perform diagnosis and different diagnostic schemes.

Indexed as

FemaleHumansImmunoglobulin Light ChainsMaleMiddle AgedMultiple MyelomaParaproteinemiasSyndecan-1Immunoglobulin Light ChainsSyndecan-1

Identifiers

PMID26025441
PMCPMC4495691
OpenAlexW2160314482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.